Objectives: To evaluate the efficacy and adverse effects of conformal concurrent chemoradiotherapy at the dose of Gy in non-surgical esophageal cancer patient at 103 Military Hospital. Subjects and methods: A cross-sectional and prospective study was performed in 66 patients who were diagnosed with non-surgical esophageal cancer at 103 Military Hospital from January 2015 to June 2018. | T¹p chÝ y - d−îc häc qu©n sù sè 1-2019 EVALUATION OF RESULTS OF CONFORMAL CONCURRENT CHEMORADIOTHERAPY AT THE DOSE OF Gy IN THE TREATMENT OF NON-SURGICAL ESOPHAGEAL CANCER AT 103 MILITARY HOSPITAL Tran Viet Tien1; Tran Van Ton1; Pham Thi Hoan1 SUMMARY Objectives: To evaluate the efficacy and adverse effects of conformal concurrent chemoradiotherapy at the dose of Gy in non-surgical esophageal cancer patient at 103 Military Hospital. Subjects and methods: A cross-sectional and prospective study was performed in 66 patients who were diagnosed with non-surgical esophageal cancer at 103 Military Hospital from January 2015 to June 2018. Results: The complete response rate was , the partial response rate was . The overall survival rate after 18 months was , the survival rate after 18 months with stages II, III and IV was 100%, , , respectively; common adverse effects were eosinophilia I (), uncommon adverse effects were complications of pneumonia (), esophageal fistula (). Conclusion: Conformal concurrent chemoradiotherapy at the dose of Gy and PF therapy significantly improves clinical symptoms, prolongs survival time, reduce complications and adverse effects. * Keywords: Esophageal cancer; Concurrent chemoradiotherapy; 3D conformal radiation therapy. INTRODUCTION According to Globocan 2012, esophageal cancer is the eighth most common cancer in the world and ranks third in gastrointestinal cancers after stomach cancer and colon cancer [3]. For non-surgical esophageal cancer, concurrent chemoradiotherapy is highly effective in significantly improving the clinical symptoms and prolonging the patient's life time. In Vietnam, there are several studies about chemoradiotherapy in the treatment of esophageal cancer, such as the study of Han Thanh Binh in 2004, Nguyen Duc Loi in 2015, but these studies were limited to 2D radiotherapy and 60 Gy high dose radiation therapy [1, 2]. Minsky's RTOG 94-05 in 2002 .
